Clinical Trial Update: Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating acute, rapid lowering of LDL cholesterol with alirocumab in STEMI patients undergoing primary PCI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-elevation Myocardial Infarction

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Population Health Research Institute | Conditions: ST Elevation Myocardial Infarction, Acute Coronary Syndrome | Phase 2 | Status: COMPLETED